Marshall Wace LLP Grows Stake in Phreesia, Inc. (NYSE:PHR)

Marshall Wace LLP increased its holdings in Phreesia, Inc. (NYSE:PHR - Free Report) by 416.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,085 shares of the company's stock after acquiring an additional 76,690 shares during the quarter. Marshall Wace LLP owned about 0.16% of Phreesia worth $2,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. ExodusPoint Capital Management LP boosted its position in shares of Phreesia by 448.6% during the fourth quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after purchasing an additional 143,077 shares in the last quarter. Barclays PLC grew its position in shares of Phreesia by 120.4% in the 4th quarter. Barclays PLC now owns 209,209 shares of the company's stock worth $5,264,000 after buying an additional 114,280 shares during the period. Norges Bank bought a new position in shares of Phreesia in the 4th quarter worth about $2,804,000. Nicholas Company Inc. purchased a new position in Phreesia during the 4th quarter valued at about $2,452,000. Finally, JPMorgan Chase & Co. boosted its stake in Phreesia by 144.2% during the fourth quarter. JPMorgan Chase & Co. now owns 145,716 shares of the company's stock worth $3,666,000 after acquiring an additional 86,040 shares in the last quarter. Institutional investors own 92.10% of the company's stock.

Phreesia Stock Performance

PHR traded up $0.33 during mid-day trading on Friday, reaching $25.56. 90,145 shares of the company traded hands, compared to its average volume of 430,030. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The company's fifty day moving average price is $25.24 and its 200-day moving average price is $24.48. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.50 billion, a P/E ratio of -17.33 and a beta of 0.82.

Wall Street Analysts Forecast Growth

PHR has been the subject of several recent research reports. Canaccord Genuity Group lifted their target price on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, March 13th. KeyCorp lowered their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. DA Davidson cut their target price on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price target on shares of Phreesia in a research report on Thursday, March 13th. Finally, Citigroup increased their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $31.33.

Insider Buying and Selling at Phreesia

In other news, COO Evan Roberts sold 16,005 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $30.00, for a total value of $480,150.00. Following the transaction, the chief operating officer now owns 748,302 shares of the company's stock, valued at $22,449,060. This trade represents a 2.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Yvonne Hui sold 1,878 shares of the business's stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total value of $44,790.30. Following the transaction, the insider now owns 28,449 shares of the company's stock, valued at approximately $678,508.65. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,660 shares of company stock worth $3,124,263 in the last three months. 5.80% of the stock is currently owned by company insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.